Testing blood-thinner treatment for clogged aortic bioprosthetic valves
Treatments studied
Part of Heart & circulation clinical trials.
This study checks whether a blood-thinning medicine can treat problems with a bioprosthetic (man-made tissue) aortic valve. It focuses on valve “clots” that can happen after either a catheter-based or surgery-based valve replacement.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an aortic bioprosthetic valve placed at least 48 hours ago
- You are age 18 or older
- You can give informed consent and agree to follow study visits and instructions
- Your kidney function is not severely reduced (creatinine must be 1.5 mg/dL or less)
- You do not have a known allergy to iodine/iodinated contrast dye
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two blood-thinning treatments after aortic valve replacement with a tissue valve. It tests if a convenient pill (apixaban) is as safe and effective as aspirin alone, to prevent blood clots and other complications. Participation could help improve recovery and reduce the risk of strokes and bleeding.
This trial compares aspirin to warfarin in the first six months after receiving a bioprosthetic (tissue) heart valve. It aims to find which treatment better prevents blood clots without causing excessive bleeding.
This study compares a blood thinner pill (a factor Xa inhibitor) with warfarin (vitamin K antagonist) in people who have had a mechanical aortic valve replacement. It looks at which option works better and is safer over the long term.
This trial compares two medicines to prevent blood clots after heart valve surgery. If you've had a tissue valve replaced or repaired, this study will see if a newer blood thinner (rivaroxaban) is safer and works better than the standard treatment.
This trial tests different blood-thinning medicines after a mitral valve repair procedure (TEER) in people who do not need long-term blood thinners. It aims to find the safest and most effective strategy to prevent blood clots.
This Phase 3 study tests whether aiming for a lower blood-thinning test result (INR) can reduce bleeding risk in people with a specific type of mechanical heart valve. The trial checks if this lower INR goal is safer while still protecting against dangerous clots.
Hear when a new Prosthetic Valve Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.